New research publication: First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants|
New research partnership with China Resources Biopharmaceutical
Tri-specific antibody for COVID-19
Researchers Show How COVID-19 Virus Triggers Immune Signaling “Storm”
Serial internalization antibody development
Novel "imbalanced" CSA bi-specific antibody
510-397-6439
3541 Investment Blvd. Suite 3, Hayward, CA 94545 USA
